Abstract 5023: Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Research

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1538-7445.AM2014-5023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Expression of indoleamine-2,3-dioxygenase 1 in sebaceous glands and related tumors of the eyelid: a potential diagnostic target

  2025cites this paper
• Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification

  2024cites this paper
• Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.

  2023cites this paper
• Assessment of an Anticancer Effect of the Simultaneous Administration of MM-129 and Indoximod in the Colorectal Cancer Model

  2023cites this paper
• Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials

  2023cites this paper
• Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

  2022cites this paper
• Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges

  2022influential citation
• Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data.

  2022cites this paper
• Immune and metabolic checkpoints blockade: Dual wielding against tumors.

  2021cites this paper
• The ups, downs and new trends of IDO1 inhibitors.

  2021cites this paper
• Recent advances in clinical trials targeting the kynurenine pathway.

  2021cites this paper
• Overview of tumor environment responsive nano-drug delivery systems in tumor immunotherapy

  2020cites this paper
• Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

  2019cites this paper
• Advanced stage melanoma therapies: Detailing the present and exploring the future.

  2019cites this paper
• Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy

  2018cites this paper
• Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

  2018cites this paper
• Targeting the IDO1 pathway in cancer: from bench to bedside

  2018cites this paper
• Mast Cells Suppress IDO-induced Metastasis in Lung Carcinoma Cells

  2018cites this paper
• Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.

  2017cites this paper
• A phase I study of indoximod in patients with advanced malignancies

  2016cites this paper
• Big opportunities for small molecules in immuno-oncology

  2015cites this paper